Based on a decade of foundational science at Baylor College of Medicine (“BCM”), Speratum – “hope” in Latin- was founded to develop an effective treatment for pancreatic cancer.
Dr. Christian Marin-Müller, Speratum’s founder and Chief Executive Officer, led the research that identified a miR-198, a powerful tumor-suppressing molecule that regulates important factors associated with the aggressiveness of pancreatic cancer.